Latest stories on VOR
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha56 · neutralgeneral
Vor Bio completes enrollment in UPSTREAM MG trial
The Fly59 · neutralproduct/pr
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Vor Bio To Participate in Upcoming September Conferences
StockTitan56 · neutralproduct/pr
Vor Bio price target raised to $27 from $18 at Wedbush
The Fly61 · neutralanalyst
Vor Biopharma reports Q2 results
Seeking Alpha50 · neutralearnings
Vor Bio reports Q2 EPS ($1.16) vs. ($251.24) last year
The Fly59 · neutralearnings
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Business Insider59 · neutralearnings
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
TipRanks56 · neutralgeneral
Vor Biopharma Inc. (VOR) files 8-K
SEC 8-K50 · neutralgeneral
Vor Bio Appoints David Zaccardelli to Board of Directors | VOR Stock News
StockTitan59 · neutralgeneral
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
Seeking Alpha63 · neutralproduct/pr
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News
StockTitan50 · neutralgeneral
Vor Biopharma Inc. (VOR) files 8-K
SEC 8-K50 · neutralgeneral
Vor Bio gains boost from telitacicept IgA nephropathy approval
TipRanks73 · bullishproduct/pr
Vor Biopharma Inc. (VOR) files 8-K
SEC 8-K50 · neutralgeneral
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China | VOR Stock News
StockTitan73 · bullishproduct/pr
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China | VOR Stock News
StockTitan73 · bullishproduct/pr
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
TipRanks63 · neutralproduct/pr
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | VOR Stock News
StockTitan50 · neutralgeneral
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference | VOR Stock News
StockTitan56 · neutralgeneral